An August 2026 FDA warning letter to R3 Medical Companies finds that products marketed as exosomes were made by a process that does not appear would isolate exosomes. What that means for practitioners who buy regenerative biologics.
CATEGORY ARCHIVE
Exosomes
Educational content about exosome therapy, MSC-derived exosomes, benefits, and applications.
Exosome Therapy for Frozen Shoulder: What the Evidence Actually Shows
Frozen shoulder is a fibrotic contracture of the joint capsule, not a tendon injury. What MSC-derived exosomes are thought to do to capsular fibrosis, and how strong that evidence is in 2026.
Exosomes for Diabetic Foot Ulcers: What the First Randomized Trial Actually Showed
A randomized controlled trial of Wharton’s jelly MSC exosomes in 110 chronic diabetic foot ulcer patients, read alongside a 2026 preclinical meta-analysis. What the data support, and what it does not.
Exosome Therapy for Sciatica: What the 2026 Evidence Actually Shows
Sciatica is driven by inflammation at the nerve root as much as by compression. Here is how MSC-derived exosomes are thought to act, and an honest read of the 2026 human evidence.
Exosome Storage and Handling: What the Cold Chain Does to Product Quality
What 50 pooled studies say about exosome storage and handling: minus 80 storage, freeze-thaw damage, formulation, and the questions to ask a supplier.
Exosome Dosing: What 66 Clinical Trials Say About Getting the Number Right
A review of 66 registered MSC-derived extracellular vesicle trials finds that route of delivery, not volume, sets the effective dose, and that only six trials reported enough detail to analyse dose at all.
Exosome Therapy vs. Hyaluronic Acid Injections for Knee Osteoarthritis
One option has decades of human trials and guideline bodies recommending against routine use. The other has promising biology and almost no controlled human data. Here is how to weigh exosome therapy against hyaluronic acid injections for knee osteoarthritis.
Exosome Therapy for Autoimmune Disease: What the 2026 Evidence Shows
A March 2026 review in Clinical Rheumatology examined exosomes as immunotherapy for autoimmune rheumatic disease. Here is what the evidence supports, where it stops, and why no exosome product is FDA approved.
Exosome Therapy for Achilles Tendinopathy: What the Evidence Actually Shows
Exosome therapy for Achilles tendinopathy is heavily marketed and thinly evidenced. Here is what the biology suggests, what the published research has and has not established, and how to evaluate the option.
Exosome Certificate of Analysis: The Four Numbers a 2026 Review Says Must Be On It
A 2026 Advanced Science review argues the exosome field must become a quantitative measurement science. Here are the four attributes it says every batch should document.
Exosome Therapy for Tennis Elbow: What the 2026 Evidence Actually Shows
Exosome therapy for tennis elbow explained: why lateral epicondylitis is degeneration not inflammation, what the cortisone and PRP data show, and where MSC-derived exosomes actually stand in 2026.
How Many Exosome Treatments Do You Need? A 2026 Guide to Course Length
How many exosome treatments do you need? See the course lengths clinics use for joints, IV, skin and hair, and what the 2026 evidence actually supports.
Exosome Therapy for Skin and Hair: What a 2026 Meta-Analysis of 39 Human Studies Found
Most claims about exosome therapy for skin and hair come from single clinics reporting on their own patients. A...
Exosome Therapy for Plantar Fasciitis: A 2026 Guide to Regenerative Heel Pain Treatment
Exosome therapy for plantar fasciitis is one of the newest questions patients bring to regenerative medicine clinics,...
Who Is a Candidate for Exosome Therapy? A 2026 Guide to Suitability and Safety
Wondering if you are a candidate for exosome therapy? Learn who benefits most, the key contraindications, and how responsible providers screen patients in 2026.
Exosome Therapy Cost in 2026: What You Are Actually Paying For
Exosome therapy cost is one of the most searched questions in regenerative medicine, and it is also one of the hardest...
What the Latest Research Says About MSC-Derived Exosomes (And What the FDA Says)
A 2025 review of 66 MSC-derived exosome clinical trials shows real progress, but there are still no FDA-approved exosome products. Here is what the research shows, what it does not, and how to read exosome claims as an informed consumer.
The Lancet Publishes Phase 3 HOPE-3 Data: What Peer Review Changes for Exosome Science
The Lancet has published the full Phase 3 HOPE-3 results for deramiocel, an investigational cell therapy whose effect is attributed to secreted exosomes. What independent peer review does and does not establish.
Exosome Therapy vs. Cortisone Shots: What the 2026 Evidence Shows
Exosome therapy vs cortisone shots compared: how each works, what the human evidence actually shows, repeat-injection risks, and FDA status in 2026.
Autologous vs. Allogeneic Stem Cell Therapy: A 2026 Patient Guide
If you are researching regenerative medicine, you will quickly meet two words that shape almost every treatment...